6-ethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester | 1429254-15-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 6-ethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
• 英文别名: tert-Butyl 6-ethoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate；tert-butyl 6-ethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 1429254-15-8
• 化学式: C₁₆H₂₃NO₃
• 分子量: 277.364
• InChiKey: QNDOJDXDNQTFEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-ethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 6.0h， 以79%的产率得到6-ethoxy-1,2,3,4-tetrahydro-isoquinoline
  参考文献：
  名称：

  SAR Based Design of Nicotinamides as a Novel Class of Androgen Receptor Antagonists for Prostate Cancer

  摘要：

  Molecular knowledge of pure antagonism and systematic SAR study offered a direction for structural optimization of DIMN to provide nicotinamides as a novel series of AR antagonists. Nicotinamides with extended linear scaffold bearing sterically bulky alkoxy groups on isoquinoline end were synthesized for H12 displacement AR binding affinity and molecular basis of antiandrogenic effect establish the optimized derivatives, 7au and 7bb, as promising candidates of second generation AR antagonists for advanced prostate cancer.

  DOI：

  10.1021/jm3014103
• 作为产物：
  描述：

  6-甲氧基-1,2,3,4-四氢异喹啉盐酸盐 在 偶氮二甲酸二异丙酯 、 水 、 氢溴酸 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.0h， 生成 6-ethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  SAR Based Design of Nicotinamides as a Novel Class of Androgen Receptor Antagonists for Prostate Cancer

  摘要：

  Molecular knowledge of pure antagonism and systematic SAR study offered a direction for structural optimization of DIMN to provide nicotinamides as a novel series of AR antagonists. Nicotinamides with extended linear scaffold bearing sterically bulky alkoxy groups on isoquinoline end were synthesized for H12 displacement AR binding affinity and molecular basis of antiandrogenic effect establish the optimized derivatives, 7au and 7bb, as promising candidates of second generation AR antagonists for advanced prostate cancer.

  DOI：

  10.1021/jm3014103

文献信息

• 一种苯并咪唑类化合物及其制备方法和在制备铁死亡抑制剂中的应用
  申请人：中山大学

  公开号：CN112939943B

  公开（公告）日：2022-09-16

  本发明公开了一种苯并咪唑类化合物及其制备方法和在制备铁死亡抑制剂中的应用。该苯并咪唑类化合物具有如式(Ⅰ)或式(Ⅱ)所示结构：本发明提供的苯并咪唑类化合物通过在R1位置引入亲脂性基团，及在R2位置引入特定的基团，得到的化合物具有较好的铁死亡抑制活性，可作为防治神经系统疾病如中风的一种先导化合物。
• T-TYPE CALCIUM CHANNEL INHIBITOR
  申请人：NISSAN CHEMICAL INDUSTRIES, LTD.

  公开号：US20160237071A1

  公开（公告）日：2016-08-18

  A novel compound that has an excellent T-type calcium channel inhibitory activity and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. The novel triazinone compound of Formula (I): where each substituent in the formula is defined in detail in the description, and R 1 could be a hydrogen atom, or a C 1-6 alkyl group, etc., E could be a 7 to 14-membered non-aromatic fused heterocyclic group, L 3 could be a C 1-6 alkylene group, etc., D could be a C 6-14 aryl group or a 5 to 10-membered heteroaryl group each of which is optionally substituted, etc., a tautomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

  一种新型化合物，具有出色的T型钙通道抑制活性，特别适用于预防或治疗疼痛、慢性肾脏疾病和心房颤动。该新型三嗪酮化合物的化学式为（I），其中公式中的每个取代基在描述中都有详细定义，R1可以是氢原子或C1-6烷基等，E可以是7-14个成员的非芳香融合杂环基，L3可以是C1-6亚烷基等，D可以是C6-14芳基或5-10个成员的杂环芳基，每个基团都可以有选择性地取代等，该化合物的互变异构体或药学上可接受的盐或溶剂化物。
• TETRAHYDROISOQUINOLINE AS LXR MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1951675B1

  公开（公告）日：2013-03-20
• SAR Based Design of Nicotinamides as a Novel Class of Androgen Receptor Antagonists for Prostate Cancer
  作者：Su Hui Yang、Chin-Hee Song、Hue Thi My Van、Eunsook Park、Daulat Bikram Khadka、Eun-Yeung Gong、Keesook Lee、Won-Jea Cho

  DOI：10.1021/jm3014103

  日期：2013.4.25

  Molecular knowledge of pure antagonism and systematic SAR study offered a direction for structural optimization of DIMN to provide nicotinamides as a novel series of AR antagonists. Nicotinamides with extended linear scaffold bearing sterically bulky alkoxy groups on isoquinoline end were synthesized for H12 displacement AR binding affinity and molecular basis of antiandrogenic effect establish the optimized derivatives, 7au and 7bb, as promising candidates of second generation AR antagonists for advanced prostate cancer.